Can I read A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin on EtoBox?

A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin by Dan Ran; Hui-juan Nie; Yu-lin Gao; Song-bai Deng; Jian-lin Du; Ya-jie Liu; Xiao-dong Jing; Qiang She is a Medicine article available to read on EtoBox.

What is A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin about?

## Background: Statin combined with ezetimibe demonstrates significant benefit in lowering low density lipid cholesterol (ldl-c) and cardiovascular events abroad, but whether intermediate intensity statins combined with ezetimibe is superior to high-intensity statin monotherapy in chinese people is unknown. ## Methods: A total of 125 patients were randomly assigned to a intermediate intensity rosuvastatin group (rosuvastatin 10mg/d, n=42), high-dose rosuvastatin group (rosuvastatin 20mg/d, n=41) or combination therapy group (ezetimibe 10mg/d and rosuvastatin 10mg/d, n=42) with a 12-week follow-up. the primary end point was the proportion of patients who achieved the 2011 esc/eas ldl-c goal <70mg/dl (1.8mmol/l) at week 12. secondary end points included changes from baseline in lipids, the occurrence of all cardiovascular events, high-sensitivity c-reactive protein and safety markers. ## Results: The combination therapy group in the primary end point was significantly higher than rosuvastatin (20mg) and rosuvastatin (10mg) at week 12 (81.0% vs 68.3% vs 33.3%, p<0.001). and the similar change was observed in reducing ldl-c levels at week 12 (67.28% vs 52.80% vs 43.89%, p<0.001). the i

Who reads A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin?

Author

Dan Ran; Hui-juan Nie; Yu-lin Gao; Song-bai Deng; Jian-lin Du; Ya-jie Liu; Xiao-dong Jing; Qiang She

Publisher

Elsevier BV

Published

2017

Language

EN

Field

Medicine (Health Sciences)